Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
TRIHETEROCYCLIC DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF
Document Type and Number:
WIPO Patent Application WO/2022/078480
Kind Code:
A1
Abstract:
A triheterocyclic derivative, and a pharmaceutical composition and an application thereof. The triheterocyclic derivative (I), and a stereisomer or a pharmacologically acceptable salt thereof have the following structure. The triheterocyclic derivative has good effects of inhibiting ATR levels in vivo and in vitro, and furthermore, the triheterocyclic derivative can also effectively treat diseases caused by abnormal ATR levels, such as cancers.

More Like This:
JP4102665Method for producing 3-amino-2-chloro-4-methylpyridine
WO/2002/019213METHOD FOR TREATMENT OF MIGRAINE USING PDE5 INHIBITORS
JP20130639871,4-DIHYDROPYRIDINE-FUSED HETEROCYCLE, PROCESS FOR PREPARING THE SAME, USE OF THE SAME, AND COMPOSITION CONTAINING THE SAME
Inventors:
LIU XIAOHUI (CN)
LIU FENGTAO (CN)
GAO DAXIN (CN)
Application Number:
PCT/CN2021/123992
Publication Date:
April 21, 2022
Filing Date:
October 15, 2021
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
SHANGHAI DE NOVO PHARMATECH CO LTD (CN)
International Classes:
C07D471/14; A61K31/437; A61K31/4375; A61K31/5377; A61P35/00; C07D487/14
Domestic Patent References:
WO2019036641A12019-02-21
WO2010037765A22010-04-08
WO2015084384A12015-06-11
WO2017180723A12017-10-19
WO2016061097A12016-04-21
WO2014140644A12014-09-18
WO2007015632A12007-02-08
WO2017123588A12017-07-20
WO2007046426A12007-04-26
Foreign References:
CN102036561A2011-04-27
CN102791715A2012-11-21
CN111205310A2020-05-29
CN109071565A2018-12-21
CN202011107416A2020-10-16
CN202110097827A2021-01-25
CN202110929213A2021-08-13
Other References:
KEVIN M. FOOTE, J. WILLEM M. NISSINK, THOMAS MCGUIRE, PAUL TURNER, SYLVIE GUICHARD, JAMES W. T. YATES, ALAN LAU, KEVIN BLADES, DAN: "Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 61, no. 22, 21 November 2018 (2018-11-21), US , pages 9889 - 9907, XP055682123, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.8b01187
JACKSON SP, NATURE, vol. 461, no. 7267, 2009, pages 1071 - 1078
CIMPRICH K.A., NATURE REV. MOL. CELL BIOL., vol. 9, 2008, pages 616 - 627
REAPER, P. M., NAT. CHEM. BIOL., vol. 7, 2011, pages 428 - 430
LECONA E, EXP CELL RES, vol. 329, no. 1, 2014, pages 26 - 34
BERGE ET AL.: "Pharmaceutically acceptable salts", J. PHARM. SCI., vol. 66, 1977, pages 1 - 19
CS, no. 140080-0
CAS, no. 1352226-88-0
Attorney, Agent or Firm:
SHANGHAI BESHINING LAW OFFICE (CN)
Download PDF:
View/Download PDF      PDF Help



 
Previous Patent: COMBINATION THERAPY FOR TREATING HEPATITIS B VIRUS INFECTION

Next Patent: REFERENCE SIGNAL DETERMINATION METHOD, REFERENCE SIGNAL PROCESSING METHOD, AND RELATED DEVICES